A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
Status
Conditions
Treatments
Details and patient eligibility
About
Patients with clinically confirmed neurofibromatosis type 1 (NF1) or neurofibromatosis type 2 (NF2) or a known neurofibromatosis (NF) mutation aged 5 years and above will be eligible to participate and will be recruited from the neurofibromatosis clinic. Given the need for identifying measures that can reliably and sensitively measure focal muscle weakness and allow for measuring muscle strength as a functional outcome in therapeutic clinical trials in NF, this pilot study will assess the reliability of measuring muscle strength in NF1 and NF2 using a hand-held dynamometer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
-
For cohort 1:
- Patients must have clinically confirmed NF1 using the NIH consensus criteria or a known NF1 mutation
- Ages 5 years and above
- < 5/5 strength on Manual Muscle Testing (MMT) testing in at least one muscle group tested on the day of enrollment
- Able to follow instructions and cooperate with exam to assess strength
-
For Cohort 2
- Patients must have clinically (NIH or Manchester criteria) or genetically confirmed diagnosis of NF2
- Ages 5 years and above
- < 5/5 strength on MMT testing in at least one muscle group tested on the day of enrollment
- Able to follow instructions and cooperate with exam to assess strength
Exclusion criteria
- No orthopedic procedure or other major surgery that could influence extremity strength in past 6 months
- No tibial dysplasia
Trial design
Primary purpose
Allocation
Interventional model
Masking
33 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal